Dr C M Thiagarajan, Chennai

• Nephrology.
• Renal Transplants.
• Induction Therapy.
• Newer immunosuppressive medication.
• High risk renal transplantation Awards & Hon.

• Chair Person in the past several Scientific Meetings organized by the ISN, ISOT and ISN (Southern Chapter).

Academic Achievement:

• Trial ink – M.O.S.T Study, Novartis Co Ltd (Completed on 30 Sep 2005), Drug: Ciclosporin.
• Tran Crept Study, Roche Co Ltd (Ongoing), Drug: Mycophenolate.
• Mofetil Victor Study, Roche Co Ltd (Ongoing), Drug: Oral Valganciclovir Vs IV Ganciclovir.
• Ascertain Study, Novartis Co Ltd (Ongoing) Drug: Enviroximes.
• Linezolid Vs. Vancomycin in the treatment of catheter related infections in haemodialysis patient, Pfizer Ltd (Partial Clinical hold)
• Porgy’s, Novartis India Ltd Drug: Mycophenolate Sodium (Ongoing).

• Senior Consultant Nephrologist and Head of the Department of Nephrology, Fortis Malar, Chennai.
• Consultant Nephrologist, Willingdon Hospital 1991 – 1998.
• Consultant Nephrologist, May Devaki Hospital 1998 – 2007

• MNAMS, (Nephrology), 1982.
• MD (General Medicine), Madras Medical College, Chennai, 1974.
• MBBS, Kalpak Medical College, Chennai, 1967

• Chennai
• India